GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2014

BioVersys, SARomics to Battle Drug-Resistant Infections

  • BioVersys, a spinoff biopharma company from the ETH Zurich focused on antibiotic resistance, is teaming up with Swedish firm SARomics Biostructures to take on antimicrobial resistance as part of an international project supported by the Eurostars initiative, which will be financing part of it through a grant.

    The aim of the SARTRIC project is to find a way to block the transcriptional activation of resistance genes with small molecules so that drugs that are already on the market will work on the resistant diseases again. The two firms will pool their resources to turn initial hit molecules into lead molecules that would be good candidates for preclinical testing.

    BioVersys and SARomics believe their specializations and expertise are complementary and should work together well. "It is a great pleasure to see the synergies between our two companies bearing fruit," BioVersys' CSO Marcel Tigges said in a statement.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »